Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.

A numerically greater change from baseline in 1-hour postdose FEV 1 was evident for aclidinium/formoterol FDC 400/12 μg compared with aclidinium/formoterol FDC 400/6 μg at all timepoints, including 24 weeks, though the improvements did not reach statistical significance except at week 4 (p < 0.05).

also in 111,027 other papers